Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

(in thousands):


	Three Months Ended March 31,
	2023		2022
Net revenues:
Clinical Services	$	114,869	$	98,791
Pharma Services	22,351		18,378
Total revenue	137,220		117,169

Cost of revenue:
Clinical Services(1)	67,292		65,267
Pharma Services(2)	15,114		13,670
Total cost of revenue	82,406		78,937

Gross Profit:
Clinical Services	47,577		33,524
Pharma Services	7,237		4,708
Total gross profit	54,814		38,232

Operating expenses:
General and administrative	61,549		66,248
Research and development	7,395		7,713
Sales and marketing	16,259		16,299
Restructuring charges	4,684		—
Total operating expenses	89,887		90,260
Loss from operations	(35,073)		(52,028)
Interest (income) expense, net	(1,467)		1,301
Other (income) expense, net	114		(168)



Loss before taxes	(33,720)		(53,161)
Income tax benefit	(2,925)		(3,753)
Net loss	$	(30,795)	$	(49,408)

(1) Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets.

(2) Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6 million of amortization of acquired Inivata developed technology intangible assets.